Navigation Links
DecisionView Board of Directors Appoints James P. Scullion as CEO and President
Date:3/31/2009

High Tech Industry Veteran Will Focus on Broader Product Distribution, Revenue Growth and Profitability

SAN FRANCISCO, March 31 /PRNewswire/ -- DecisionView, Inc., the leading provider of Clinical Optimization Solutions for the Life Sciences industry, today announced that its Board of Directors has appointed James P. Scullion to the role of Chairman, President and CEO of DecisionView, effective immediately. Most recently, he held the role of Chairman for DecisionView. Scullion succeeds Steve Andrade as the Company's President and Chief Executive Officer.

"I'm very pleased that Jim has agreed to join DecisionView as its new CEO," said Chris Hollenbeck, a DecisionView Board Member. "We believe the market for clinical optimization solutions is poised for significant growth. Jim has over two decades of experience leading high tech companies, and his expertise will greatly benefit DecisionView as the company looks to extend its leadership position as a comprehensive provider of business performance optimization applications."

Mr. Scullion brings more than 20 years of experience as a "C" level executive in the high technology industry to his new position. Most recently, he served as Chairman and CEO of Tumbleweed Communications from January 2006 to September 2008. Under Mr. Scullion's leadership, Tumbleweed was successfully transformed from an email security centric company to a leading provider of secure content delivery solutions to Global 1000 and midmarket enterprises doubling its customer base from 1,700 to 3,500 customers. Tumbleweed was acquired by Sopra Group in September 2008. From January 2004 to January 2006, he was CEO of ComnetiX, Inc., a leading provider of criminal intelligence systems. During Mr. Scullion's tenure at ComnetiX, revenues grew threefold and he led the company's successful IPO on the Toronto Stock Exchange. From 1990 to 2002, he held senior management positions including President and COO with Identix Incorporated, a publicly traded biometric technology company. While at Identix, Scullion led the company's growth in annual revenues from $1 million to more than $80 million.

"DecisionView is the technology leader in the clinical recruitment optimization market," said Scullion. "I am excited to be joining a company that is well positioned to capitalize on a fast growing, high demand market. I believe my leadership and operational experience will further strengthen the already outstanding DecisionView team, and will help accelerate our company's growth as we expand and enrich our optimization solutions for the Life Sciences industry."

Steve Andrade will be leaving the company to pursue other interests and will also be stepping down from his position as a member of the DecisionView board of directors.

About DecisionView, Inc.

DecisionView develops innovative software solutions that optimize the clinical performance of life sciences organizations around the world. By uniquely converging predictive analytics, simulation, visualization and data aggregation capabilities into functionally rich and easy to use applications, the company's solutions deliver proven business value in faster cycle times, reducing clinical costs and improving clinical productivity. To learn more, visit www.decisionview.com.


'/>"/>
SOURCE DecisionView, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DecisionView Unveils the Next Generation of Clinical Trial Software: StudyOptimizer 4.0
2. Andrew Dallas, President of Full Spectrum Software Appointed to Medical Device and Diagnostic Industry Magazine Editorial Advisory Board
3. Nutrition 21s President and CEO, Elected to the Consumer Healthcare Products Association Board
4. Ingenious Med Expands Leadership and Adds Members to Board of Directors
5. AORN and Mercy Ships Collaborate to Increase Patient Care Aboard Hospital Ships
6. Loop Joins Board of Management Health Solutions, Inc.
7. Gen-Probe Board of Directors Elects Carl Hull Chief Executive Officer
8. TrinityCare Appoints Kirk B. Shulke, M.D. to Board of Directors
9. RiskMetrics Affirms Recommendation that Stockholders Support LCA-Vision Board of Directors and Reject All Proposals by Dissident Joffe Group
10. TrinityCare Appoints Decorated Christian Artist Al Denson to Board of Directors
11. Former Merck Executive Joins Board of Clinical Information Network, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Contrary to popular perception, ... is declining—and at noteworthy rates. Between 2002 and 2014, Salas-Wright and his colleagues ... violence in the United States. The study, Trends in Fighting and Violence ...
(Date:4/21/2017)... SALT LAKE CITY, Utah (PRWEB) , ... April ... ... leading provider of wilderness therapy treatment for adolescents and young adults, has kicked ... Thursday, April 20th-Sunday, April 23rd. This year’s theme is “Attachment Informed Therapy ...
(Date:4/21/2017)... ... 2017 , ... Young Asset Protection, an insurance provider and ... greater Pittsburgh metropolitan region, is joining forces with the local chapter of the ... , Variety the Children’s Charity is a national organization dedicated to empowering, enabling, ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... The adage ... Flex House, the next project in the company’s esteemed VISION House demonstration project series. ... use exactly the amount of resources they need to live affordably and abundantly without ...
(Date:4/21/2017)... ... April 21, 2017 , ... The ... of Record (AOR) for Theravent, Inc. , the makers of a revolutionary ... Foundation Consumer Healthcare, is now working to expand distribution in anticipation of a ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Eyevensys, a private biotechnology company developing its ... that enables the safe, local, sustained production of therapeutic ... of ophthalmic diseases, announces it has received approval from ... to advance its technology into clinical development. ... The EyeCET platform uses ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
Breaking Medicine Technology: